Purpose DFP-10917 is a novel deoxycytidine analog with a unique mechanism of action. Brief exposure to high concentrations of DFP-10917 inhibits DNA polymerase resulting in S-phase arrest, while prolonged exposure to DFP-10917 at low concentration causes DNA fragmentation, G2/M-phase arrest, and apoptosis. DFP-10917 demonstrated activity in tumor xenografts resistant to other deoxycytidine analogs. Experimental design Two phase I studies assessed the safety, pharmacokinetic, pharmacodynamic and preliminary efficacy of DFP-10917. Patients with refractory solid tumors received DFP-10917 continuous infusion 14-day on/7-day off and 7-day on/7-day off. Enrollment required age > 18 years, ECOG Performance Status 0-2 and adequate organ function. /day on the 14-day and 7-day continuous infusion schedules, respectively. Preliminary activity was suggested. Pharmacodynamic data demonstrate biological activity at the tested doses.
Introduction
Many nucleoside analogs have been developed as anti-tumor agents that are effective through interruption with the synthesis of nucleic acids [1] . Among them, gemcitabine is a representative deoxycytidine analog used clinically as an antitumor agent in the treatment of various tumor types [2, 3] . Gemcitabine is activated through phosphorylation; the phosphorylated form inhibits the activity of DNA polymerase preventing DNA synthesis causing S-phase arrest [4, 5] . Since the great efficacy of gemcitabine in combination with radiotherapy or other antitumor agents for the treatment of solid tumors was shown, newer nucleoside antimetabolites have gained attention [6] .
DFP-10917 [4-amino-1-(2-cyano-2-deoxy-β-Darabinofuranosyl)-2(1H)-pyrimidinone or CNDAC] is a nucleoside analog similar to deoxycytidine [7, 8] . This compound formerly known as TAS-109 has a novel chemical property and was designed as a mechanism-based DNA selfstrand-breaking nucleoside. DFP-10917 and its prodrug (Sapacitabine also known as CYC682) have been studied extensively in vitro tumor models and have a cytotoxic effect against a wide range of cancer cell lines. Similar to other deoxycytidine analogs (cytarabine and gemcitabine), this compound is activated by deoxycytidine kinase (DCK) and is inactivated by cytidine deaminase (CDA) [6] . Additionally, DFP-10917 induces DNA strand breaks by beta-eliminationmediated mechanism after incorporation into the DNA strand. CNddC [4-amino-1-(2-cyano-2,3-didehydro-2,3-dideoxy-ß-D-arabinofuranosyl)-2(1H)-pyrimidinone] was detected in the nucleosides extracted from cells treated with DFP-10917, where the presence of CNddC is indicative of DNA self-strand-breakage [9] . DFP-10917 is converted to DFP-10917-triphosphate, which is incorporated into DNA (without inhibiting DNA polymerase) causing the DNA strand breaks. As a result, DNA repair is then initiated by checkpoint regulators, which causes G2/M-phase arrest and ultimately results in cell apoptosis [10] , unlike S phase arrest for similar deoxycytidine analogs. In this in vitro phenomenon, DFP-10917-triphosphate is incorporated into DNA strand as DFP-10917-monophosphate to a comparable level in a concentration-and time-dependent manner [11] .
In vivo study using nude mice implanted with human colon adenocarcinoma was performed in order to determine the optimum dosing schedule. DFP-10917 was administered using various dosing schedules; anti-tumor activity was evaluated on each schedule and compared to that of gemcitabine administered as an intravenous bolus injection. The results suggested that prolonged exposure to DFP-10917 by 14-day continuous infusion at a low concentration provides an optimal anti-tumor activity that was superior to that of gemcitabine ( Fig. 1, xenograft model) . In addition, the least body weight loss was observed in mice on the 14-day continuous infusion schedule. Exposure to low dose DFP-10917 showed DNA strand break in comet assay (Fig. 1) . Relative plasma concentrations of DFP-10917 were observed using the 14-day continuous infusion, while the myelosuppressive effects as seen in leukocyte and platelet count depressions were of lesser magnitude. The linear relationship between dose administered, and AUC and C max was preserved across dose levels and infusion times. Thus, prolonged exposure of DFP-10917 at low concentrations was suggested to cause less myelosuppression while having greater tumor inhibitory efficacy than shorter high dose administration.
On the basis of these preclinical data, we planned phase I studies of DFP-10917 in patients with advanced solid tumors using a continuous infusion administration regimen at a low concentration. The objectives of two phase I studies were to determine the maximum-tolerated dose (MTD), the dose recommended for phase II study and the dose-limiting toxicity (DLT) of DFP-10917 given by 14-day continuous infusion or 7-day continuous infusion in patients with advanced solid tumors. In addition, these studies assessed the safety, pharmacokinetic, pharmacodynamic and preliminary efficacy of DFP-10917.
Patient and methods
Patient eligibility Patients had a pathologically-confirmed malignancy that was advanced or locally advanced solid tumor and was refractory to standard therapy or for which conventional therapy was not reliably effective or no effective therapy was available. They were required to be ≥18 years old, had an Eastern Cooperative Group performance status of 0-2. Patients with physiologically adequate organ function were eligible for this study. The following laboratory values, performed within 28 days prior to start of treatment must be satisfied [absolute neutrophil count ≥1.5 × 10 9 /L, platelets ≥100 × 10 9 /L, plasma creatinine ≤1.5 × upper limit of normal (ULN) for the institution, bilirubin ≤1.5 × ULN, alanine transaminase (ALT) and aspartate transaminase (AST) ≤ 2.5 × ULN (transaminase levels could be ≤5.0 × ULN if the patient had liver metastases)]. These patients had a measurable or non-measurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) [12] .
The study protocol, amendments, and informed consent form were reviewed and approved by the Institutional Review Board. The study was conducted in accordance with International Conference on Harmonization Good Clinical Practice, the protocol, all applicable regulatory requirements, and the guiding principles of the Declaration of Helsinki. Written informed consent to participate in the study was obtained from each patient before study enrollment and the performance of any study-specific procedures. These studies received cooperation from Theradex (Princeton, USA).
Study drug DFP-10917 was supplied in vials as a lyophilized product and was stored between 2 and 8°C. Patients received DFP-10917 via 14-day or 7-day continuous infusion using a central venous access device with an infusion pump. The appropriate dose was withdrawn from the vial and diluted with sodium chloride injection (United States Pharmacopeia) in a 250-mL container. The infusion solution was administered using an ambulatory pump at a temperature of not more than 25°C. The solution was used immediately after reconstitution and the administration finished within 240 h. For single infusion bag administrations infused over a period of more than 4 days (96 h), an insulated pouch and a frozen 12-oz gel pack were used and replaced by the patient every 12 h. The dose was calculated based on the patient's actual weight at the beginning of each cycle.
Study design and treatment This was a phase I, multicenter, single arm, open-label study of DFP-10917 given by a continuous 14-day or 7-day central intravenous infusion to patients with advanced solid tumors. The first phase I study was to perform a treatment cycle for 3 weeks in duration, comprised of a 14-day continuous infusion followed by a 7-day rest period, and then a treatment cycle for 2 weeks in duration, comprised of a 7-day continuous infusion followed by a 7-day rest period (to assess for two cycles). The starting dose of 3.0 mg/m 2 /day was based on the highest non-severely toxic dose observed in dogs (1.0 mg/kg/day) determined in a dosing study using a continuous infusion.
Patients were enrolled in ascending dose cohorts of 3 to 4 patients and monitored for evidence of DLT and plasma concentration. DLT was defined as any grade 3 or 4 nonhematologic toxicity; nausea/vomiting of grade 3 or greater despite maximal antiemetic therapy or grade 3 or greater diarrhea despite maximal antidiarrheal therapy; any grade 4 neutropenia of greater than 4 days duration or grade 3 associated with fever; grade 4 thrombocytopenia or any treatment delay of greater than 2 weeks due to drug-related side effects. The MTD was defined as one dose level below the dose at which DLT was observed in at least 2 patients. At least 6 patients were to be enrolled and treated at the MTD with no more than one of these patients experiencing DLT. Dose modifications Dose escalation was guided by the observance of drug-related toxicities and dose-limiting toxicities (DLTs). Patients were treated in cohorts of at least three patients beginning at the starting dose level of 3.0 mg/m2/day. If no Cycle 1 DLT was observed in the first three patients, then the next cohort would be enrolled at an escalated dose level (dose doubling). If one patient in a cohort experienced a ≥ grade 2 drug-related toxicity (not dose-limiting), then dose escalation continued using 50% increments of the preceding dose. If more than one patient experienced a ≥ grade 2 drugrelated toxicity or any non-related grade 3 or 4 toxicity (not dose-limiting), then dose escalation continued using 33% increments of the preceding dose. For both hematologic and non-hematologic clinically significant grade 3 or 4 toxicities, treatment ceased to allow for recovery. Toxicity had to recover to ≤ Grade 2 by study Day 21 for the patient treated with a subsequent cycle. If the patient recovered to ≤ Grade 2 by study Day 21, the next cycle began with the dose reduced by one dose level and the dose was not re-escalated for subsequent cycles for that patient. Any patient who had received a Fig. 1 Schedule-dependency of the antitumor activity of DFP-10917 against KM20C cell line in xenograft model (Dose: Gemcitabine iv; 300 mg/kg/day, DFP-10917 iv; 500 mg/kg/day, DFP-10917 1-day CI; 30 mg/kg/ day, DFP-10917 3-day CI; 8 mg/kg/day, DFP-10917 14-day CI; 4.5 mg/kg/day) and DNA fragmentation of HeLa cells by treatment with DFP-10917 for 3 days in comet assay (Concentration: IC 50 as a result of exposure for 10 days) dose ≤3.0 mg/m2/day and experienced an adverse event that required a dose modification for subsequent cycles would have his or her dose reduced by one dose level. In other words, those patients who experienced a Grade 3 or Grade 4 adverse event during the 14-day treatment cycle had to recover to Grade 2 by Day 21 (1 week after the cycle-recovery week) in order to be treated in the next cycle. If a patient did not recover to Grade 2 by Day 21, the patient could be allowed another week of recovery (up to Day 28) . In this case, the patient had to recover to Grade 1 in order to be treated in the next cycle. In case of any Grade 3 or 4 toxicity after one dose reduction, patient was removed from the study. Also, if more than one dose reduction was required, the patient was removed from the study.
Patient evaluation All patients who received a dose of study medication are included in the safety analysis. Safety parameters included adverse events, vital signs, and clinical laboratory results. Adverse events were classified according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0 [13] .
Patients were evaluated every 2 cycles by 14-day infusion (or every 4 cycles by 7-day infusion) for tumor response and evidence of disease progression using the Response Evaluation Criteria in Solid Tumors (RECIST 1.0) methodology [12] . All patients who completed 2 cycles (or 4 cycles) of study therapy were considered evaluable for efficacy. For patients who received less than 2 cycles (or 4 cycles) of study therapy, clear evidence of clinical progression had to be present to be considered evaluable for efficacy. Patients with an initial positive response were to be confirmed at least 4 weeks later. Overall best response is defined as the highest-ranking response assessment (treating unconfirmed responses as SD). Valid response assessments are CR (complete response), PR (partial response), SD (stable disease) and PD (progressive disease).
Pharmacokinetics assessments Blood samples and urine specimens were collected for measurement of DFP-10917, the metabolite CNDAU, and the identification of unknown metabolites. Blood was collected at the following times: Day 1 at pre-dose, and 30 min, and 1, 2, 4, and 8 h post-infusion; on Day 8 (or Day 4 by 7-day infusion), before replacing the infusion bag; and on Day 15 (or Day 8 by 7-day infusion) immediately, and 5, 15, and 30 min, and 1 and 2 h post-infusion. Urine was collected during Cycle 1 on Day 1 for 0-24 h by 14-day infusion, and either on Day 4 or on Day 7 for 0-24 h by 7-day infusion. Pharmacokinetic parameters evaluated included: concentration at steady state (CSS), area under the concentration-time curve (AUC), drug half-life (T½), volume of distribution (Vd), and drug clearance (CL) for DFP-10917 and CSS for metabolite CNDAU at each dose level. Also evaluated were the urinary excretion rates of DFP-10917 and CNDAU at each dose level. Levels of DFP-109 and CNDAU in plasma and urine were quantitated in validated assays using a high-performance liquid chromatography coupled with a tandem mass spectrometer with electrospray ionization (LC/MS/MS). The pharmacokinetic samples were measured by Mitsubishi Chemical Medience Corporation (Tokyo, Japan). The lower limit of quantification was 0.5 ng/mL for DFP-10917 and 2.5 ng/mL for CNDAU in plasma. PK parameters were calculated using WinNonlin (Version 4.1, Pharsight) software.
Pharmacodynamic assessments Optional blood samples were collected for the following exploratory pharmacogenomics studies: cytidine deaminase (CDA) levels and DNA genotyping [14] , RNA gene expression analysis at pre-dose and at end of infusion. The CDA enzyme is involved in the metabolism of DFP-10917. In the DNA genotyping study, the presence of the CDA G208A allele was assayed by DNA sequencing. People with a novel polymorphism of CDA (G208A) may have a decreased ability to metabolize DFP-10917 possibly contributing to DFP-10917 sensitivity (toxicity). Briefly, a portion of the gene containing the polymorphism was amplified from blood samples using PCR and the amplified DNA was sequenced to determine the presence of the G208A polymorphism. The distribution of CDA polymorphisms among the tested patients was determined. In the RNA expression analysis of CDA, whole blood samples were assayed for the expression of CDA mRNA using RT-PCR. Relative levels of mRNA were analyzed using an Applied Biosystems (ABI) 7900 HT sequence detection system using TaqMan® chemistries. The cDNA samples were amplified and analyzed in triplicate. With the exception of one sample, triplicate data for all samples were within +/− 2 Cts. Assay limits of measurement were: all CDA data were analyzed at 35.0 Cts or less, and data for the reference gene ACTB were analyzed at 30.0 Cts or less. The pharmacodynamic samples were measured by Gentris Corporation (Morrisville, USA).
In this Proof of Concept study, whole blood sample specimens were collected for assessment of DNA strand breakage prior to and following DFP-10917 administration by 7-day infusion. The DNA strand breakage assessment (Comet Assay) was measured by BioReliance Corporation (Rockville, USA). Blood samples from the patients were collected at pre-dose (Day 1) and at the end of infusion (Day 8). After collecting each sample, they stored at 2-8°C and transferred to the lab to be processed into slides and placed in lysis solution. The comet assay for the blood samples was performed under alkaline buffer condition (pH 13) with 20 min of unwinding time and 30 min of electrophoresis (0.7 V/cm) at room temperature. Two slides from each sample were used for scoring and fifty cells per slide for a total of 100 cells per sample were scored. DNA damage was measured using an automated scoring system (Comet Assay IV v 4.11). The amount of DNA damage was represented as the length and number of fragmented DNA that migrated outside the cell nucleus (comet tail). Pair-wise comparison (t-test) was used to compare the % tail intensity from the group mean of the vehicle controls and % tail intensity from the group mean of the positive control to determine acceptance criteria of a valid test [15, 16] .
Results
Patient characteristics A total of 29 patients were enrolled in the studies. The first patient was enrolled in the study August 2005, and the final patient was removed from the study in October 2007. The patient characteristics for each 14-day and 7-day infusion are summarized in Table 1 . Fifteen patients were enrolled and treated in the 14-day infusion study. The median duration of disease was 25.6 months (range: 15-68 months). Fourteen patients were enrolled and treated in the 7-day infusion study. The median duration of disease was 20.2 months (range: 6-58 months).
Toxicity All 29 patients were evaluated for safety, and 28 patients (93.3%) experienced at least one adverse event in these studies. A number of patients with DFP-10917 related adverse events for each 14-day and 7-day infusion are summarized in Table 2 .
In 14-day infusion, cycle 1 dose-limiting toxicities (DLTs) were observed in all 3 patients treated at the 4.0 mg/m 2 /day dose level and were primarily hematologic: grade 4 neutropenia (3 patients), grade 3 febrile neutropenia (2 patients), and grade 4 thrombocytopenia, grade 3 anemia, grade 3 leukopenia (1 patient each). grade 3 hyperbilirubinemia and grade 3 dyspnea were also reported for 1 patient. In addition to these DLTs, cycle 2 drug-related severe events were reported for 2 patients in the 3.0 mg/m 2 /day cohort which included grade 3 or 4 neutropenia, grade 3 febrile neutropenia and grade 3 pneumonia. Serious adverse events were reported for 53.3% of patients; of these, 26.7% of patients had serious adverse events considered to be related to study therapy which included febrile neutropenia (20.0%), anemia (13.3%), and thrombocytopenia, pneumonia, or hyperbilirubinemia (6.7% each). One patient (6.7%) discontinued study therapy due to multiple study-related serious adverse events: neutropenia, thrombocytopenia, hyperbilirubinemia, anemia, and dyspnea. The only patient death reported was considered to be due to progressive disease and unrelated to study therapy. Regardless of relationship or severity the hematologic adverse events reported for ≥20% the patients were neutropenia (60.0% of patients), anemia (53.3%), febrile neutropenia (26.7%) and leukopenia (20.0%) and the non-hematologic adverse events were fatigue, nausea (66.7% each), alopecia, diarrhea (46.7% each), constipation (40.0%), vomiting (33.3%), pyrexia (26.7%), and back pain, dizziness, dyspnea, headache, hypokalemia, or stomatitis (20.0% each).
In 7-day infusion, during cycle 1, one patient treated at 4 mg/m 2 /day DFP-10917 had a DLT of grade 3 febrile neutropenia lasting 5 days. During cycle 2, one patient treated at 4 mg/m 2 /day DFP-10917 had a grade 4 neutropenia DLT lasting 8 days, and one patient treated at 3 mg/m 2 /day DFP-10917 had a DLT of grade 3 neutropenic fever that lasted 10 days. Serious adverse events were reported for 64.3% of patients. 14.3% of patients had serious adverse events considered to be related to study therapy; those events were grade 3 febrile neutropenia reported by one patient, and grade 3 neutropenic fever and grade 3 anemia reported by the other patient. One patient had multiple acute brain infarcts that resulted in the patient's death; the event was considered unlikely to be related to study drug. Regardless of relationship or severity, the adverse events reported for ≥20% of the patients were anemia In the 7-day infusion cohort and out of 11 patients, 3 required dose reductions prior to cycle 3; 7 patients entered cycle 4 of which 1 had dose reduction; 3 patients entered cycle 5 and 1 required dose reduction. No further dose reduction was required. In the 14-day infusion cohort and out of 5 patients, 1 patient required dose reduction prior to cycle 3; All 5 patients entered cycle 4 without any dose reduction; 2 patients entered cycle 5 and no dose reduction was required; 1 patient entered cycle 7 and required dose reduction. Pharmacokinetics The pharmacokinetics parameters of DFP-10917 and urinary excretion rate for each 14-day and 7-day infusion are summarized in Table 3 . The CSS graphs for 7-day and 14-day infusions are shown in supplemental Fig. 1 . When DFP-10917 was intravenously infused continuously at doses of 2.0, 3.0 and 4.0 mg/m 2 /day for 14 days, the mean areas under the concentration-time curve (AUC) were 720.8, 1140.4, and 1794.2 ng•hr./mL, respectively. Mean CSS at these doses were 2.06, 3.21, and 4.90 ng/mL, respectively, showing a dose-dependent increase (Fig. 2a) . At each dose level, the half-life (T 1/2 ) was 0.8, 1.0 and 0.9 h, the volume of distribution (Vdss) Efficacy In 14-day infusion, the median number of DFP-10917 cycles administered was 2 (range: 1-8 cycles, Fig. 3) and the median duration of exposure was 36 days (range: 4-183 days). Of the 13 patients evaluable for response, none experienced a complete or partial response to therapy; 5 patients (38.5%) had SD as their best response (4 colorectal cancers and 1 non-small cell lung cancer). The median time to disease progression was 53 days.
In 7-day infusion, the median number of DFP-10917 cycles administered was 3 (range: 1-16 cycles, Fig. 3 ) and the median duration of exposure was 42 days (range: 8-237 days). Of the 9 patients evaluable for response, no objective tumor response was observed. Three patients (33.3%) had SD as their best response (2 colorectal cancers and 1 salivary gland cancer). Six patients (all treated at 3 mg/m 2 /day) had progressive disease as their best response to treatment. The median time to disease progression was 62 days.
Pharmacodynamics In 14-day infusion, the genomic DNAs were purified from 15 whole blood samples and CDA genetic polymorphisms (G208A) were genotyped using DNA sequencing method. The genotypes of all samples were found to be GG (homozygous for the wild-type allele). Total RNAs were purified from 15 whole blood samples and the CDA gene expression levels measured using the RT-PCR method. CDA relative gene expression levels (CDA/ACTB) of all samples could be detected with the lowest value 0.0057 and the highest value 0.0167. Each CDA/ACTB of three patients with DLT was 0.0087, 0.0068 and 0.0102, or each CDA/ ACTB of five patients with SD was 0.0072, 0.0095, 0.0080, 0.0066 and 0.0096.
In 7-day infusion, the genomic DNAs were purified from 11 whole blood samples and the genotypes of all samples were found to be GG (homozygous for the wild-type allele). Total Table 3 Pharmacokinetic parameters of DFP-10917 and urinary excretion rate in the first treatment cycle Duration Dose levels (mg/m 2 / day) n Pharmacokinetic parameters Urinary excretion rate until 24 h (% of dose)
CNDAU Total mean ± SD mean ± SD mean ± SD mean ± SD mean ± SD mean ± SD mean ± SD mean ± SD A total of 17 samples from 10 patients were assessed for DNA damage using the Comet Assay by 7-day infusion. Seven of ten patients had samples for Day 1 (time point 0) and Day 8 (the end of infusion). The percentage of tail intensity on Day 8 was 1.29 to 22.25 times greater than on Day 1. There were two patients for over the 40 of the % tail intensity at Day 8. The patient of value 47 observed DLT, and the patient of value 41 treated until 16 cycles (Fig. 3) .
Discussion
DFP-10917 was generally well tolerated and was feasible administration despite 14-day or 7-day continuous infusion. The predominant drug-related and severe toxicities were hematologic; non-hematological events were infrequent in patients with solid tumors. DLTs and the most frequently observed adverse events were neutropenia, anemia, febrile neutropenia, leucopenia, and thrombocytopenia. Although, the most frequently observed non-hematologic drug-related adverse events were fatigue, nausea, vomiting, diarrhea, and alopecia. The adverse effects of DFP-10917 observed in these phase I studies were consistent with the finding of the preclinical toxicology studies. Based on the DLT profile seen at the DFP-10917 dose of 3.0 and 4.0 mg/m 2 /day by continuous /day, and 5 of the 13 evaluable patients (38.5%) were experienced disease stabilization (Fig.  3) . Therefore, the dose of 2.0 mg/m 2 /day administered by a continuous 14-day central intravenous infusion was determined to be the recommended phase II dose/regimen in patients with solid tumors.
Correlation charts of DFP-10917 dose versus DFP-10917 concentration at steady-state (CSS) and versus the area under the concentration-time curve (AUC) for each continuous infusion are shown in Fig. 2 . In a dose range of 2.0-4.0 mg/m 2 / day with 14-day continuous infusion, the CSS concentration of DFP-10917 and the AUC appeared to increase in dosedependent fashion and there was a good positive correlation. The differences in mean values among the 3 dose levels of other parameters (T 1/2 , Vdss, and CL) by 14-day continuous infusion appeared not to be large. Pharmacokinetic parameters were calculated by 1-compartment model analysis, and the difference between the determined values of DFP-10917 concentration and values estimated after the model analysis was not large. These pharmacokinetic parameters were approximately similar by 7-day infusion and the results were likely to be consistent. Meanwhile, the CSS concentration of CNDAU for the DFP-10917 metabolite is provided insight into the inactivation of DFP-10917 and the influence of inactivating enzyme, CDA. The CSS concentration of CNDAU for a dose range of 2.0-4.0 mg/m 2 /day had a tendency to increase in a dose-dependent fashion, and there was no connection with DLT patients (Fig. 2e) . However, it was suggested that there was an association between the low rate of DFP-10917-CSS to CNDAU-CSS and the DLT patients (Fig.  2f) . It was known that higher Cmax and AUC values of CNDAC (the same compound as DFP-10917) by the oral prodrug of CNDAC (Sapacitabine) were associated with greater percentage decrements in absolute neutrophil counts and the occurrence of the worst grade of neutropenia [17] . There was the same tendency for that association for this study, and it was estimated that the rate of DFP-10917-CSS to CNDAU-CSS was one of the monitoring markers for toxicity as low dose and long period continuous infusion of DFP-10917. Meanwhile, the mean urinary excretion rate of DFP-10917 until 24 h after starting infusion was lower than the rates for CNDAU of the DFP-10917 metabolite, and there was no significance ascribed to the difference of dose. These characters were also observed in Sapacitabine, the oral prodrug of DFP-10917 [18] . Therefore, these results indicate that after DFP-10917 administered in the continuous intravenous infusion was mainly metabolized in the liver, it was excreted in urine as the metabolite CNDAU or further metabolite, and there was no significant difference in the pharmacokinetic parameters or urinary excretion rates between 14-day and 7-day continuous intravenous infusion periods. (i.e., continuous intravenous infusion for).
The metabolic pathway of DFP-10917 is almost the same as cytarabine and gemcitabine. These deoxycytidine analogs are inactivated by the enzyme CDA. Homozygous G208A # Not evaluable (NE) patient for tumor response. ** The measurement of Comet tail migration by Comet assay scoring at day 8 of the end of infusion alteration in CDA was reported to cause the severe drug toxicity by gemcitabine treatment in a Japanese cancer patient [19, 20] , and the allelic frequency of the G208A polymorphism of the CDA gene in the Japanese population was 4.3% [14] . It was reported that the SNP G208A was not detected in Europeans, whereas the allelic frequency of 208A was 0.125 in Africans [21] . Frequencies of homozygous G208A individuals in the Japanese and African populations were estimated to be about 0.18% and 1.56%, respectively [19] . In these DFP-10917 studies, there were three African patients, and all patients were the wild-type allele. Therefore, the observed serious adverse events were not due to the G208A polymorphism of the CDA gene.
High activity of CDA, the degrading enzyme of deoxycytidine analogs, plays an important role in the development of resistance to these agents [22] . For example, CDA activity proved to be significantly higher in patients with cytarabine refractory AML than in untreated patients [23] . Furthermore, it was shown that most solid tumor cell lines had increased CDA activities, whereas 10 neuroblastoma lines showed extremely low activity, and low CDA activity may contribute high sensitivity to gemcitabine [24] . On the other hand, it was reported that there was no observation a correlation between CDA mRNA levels at a prognostic factor for survival either [25] . In small samples of these DFP-10917 studies, there was no detection a correlation with five times value range between CDA expression level and toxicity and efficacy. The correlation of CDA expression with sensitivity to DFP-10917 remains controversial and needs additional exploration.
The comet assay has become established as a highly sensitive technique for measuring DNA strand breaks [26, 27] and was set as a secondary pharmacodynamic endpoint in this trial. Several studies had examined blood of cancer patients who are undergoing chemotherapy compared to pre-treatment measurements, the tail moment for anti-neoplastic drugs were under 2 times or 3 times [28, 29] . Since all samples of the % tail intensity enhanced before and after DFP-10917 administration, 1.29 to 22.25 times, this result indicated that a DNA strand breakage may have occurred. However, the % tail intensity was not always observed at high levels in all patients. Based on historical controls, DNA damage data (% tail intensity) with saline, methyl methanesulfonate (10 μg/mL) and bleomycin (0.375 μg/mL) were 14, 89 and 56, respectively. Tail intensities greater than 40 were observed in two patients, one patient with prolonged SD and one patient with a DLT. This observation suggests that DNA double-strand break measurements by comet assay can potentially be used to evaluate response to DNA damage agents (such as DFP-10917). The comet assay can also possibly serve as a surrogate assay for efficacy and pharmacodynamics monitoring of such agents in future studies.
In conclusion, these studies investigated the differential toxicity and pharmacokinetics of 14-day and 7-day continuous infusions that were selected based upon preclinical studies. Continuous infusions of DFP-10917 are feasible and well tolerated with myelosuppression as main DLT. The recommended doses are 2.0 mg/m 2 /day and 3.0 mg/m 2 / day on the 14-day and 7-day continuous infusion schedules, respectively. Stable disease was the best antitumor response observed in this heavily pretreated population. Pharmacodynamic data demonstrate biological activity at the tested doses. Based on the results of the phase I studies, a phase II trial of DFP-10917 to evaluate the safety and efficacy of this agent in patients with advanced colorectal cancer refractory to cytotoxic chemotherapy was conducted (NCT00824161).
